Advertisement

Topics

Companies Related to "Comparison of the Effect Between Levofloxacin and Moxifloxacin Among MDR-TB Patients" [Most Relevant Company Matches] RSS

04:46 EDT 16th August 2018 | BioPortfolio

Here are the most relevant search results for "Comparison of the Effect Between Levofloxacin and Moxifloxacin Among MDR-TB Patients" found in our extensive corporate database of over 50,000 company records.

Showing "Comparison Effect Between Levofloxacin Moxifloxacin Among Patients" Companies 1–25 of 3,700+

Relevant

Imposter Research

IMPOSTER is the name of a medical research study of patients with muscle symptoms while taking cholesterol lowering therapies called statins. Several important findings from this study have been published and have raised questions about the safety of statin therapy for patients with muscle complaints. This website was developed to address those questions and to share what is known about statin mu...


Eminent effect

The eminent effect is a consultancy aiming to stand out from the crowd in tackling many of today’s people and business challenges. The company offers organisation specific training, development, sales/marketing and interim management solutions not off the shelf packages.Primarily working within the NHS, Pharmaceutical and Biotechnology sectors, the eminent effect personnel can offer experience g...

ZHEJIANG WONDERFUL PHARMA & CHEM CO.

ZHEJIANG WONDERFUL PHARMA & CHEM CO. are always developing new products exclusively to meet our customers needs of antineoplastic bulk drugs both fine chemicals and plant extracts in close collaboration. Follows are our new products: Atorvastatin Ca Stavudine Erdosteine Zoledronic acid or Sodium Zidovudine Moxifloxacin HCl Exemestane Bicalutamide


Sangamo BioSciences, Inc.

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy and a Phase 2 trial in ALS. Sangamo also has two Phase 1 clinical tri...

DestinationRx

Since its inception in 1999, DestinationRx has grown from a pioneer in consumer drug comparison and purchasing to a recognized health plan and drug comparison industry leader. The company provides the healthcare industry with the educational, strategic, and transaction-support tools necessary for their customers and patients to navigate today’s complex ...

Contura Inc.

Aquamid is composed of 97.5% water for injection and 2.5% cross-linked polyacrylamide. The patented hydrogel is homogeneous: it contains no micro particles; hence its filling effect is due solely to the injected volume. Unlike particle-based fillers, the hydrogel does not rely on an intended foreign body reaction to achieve the desired augmentation. Therefore, the filling effect is immediate and p...

Aranesp

Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia associated with chronic renal failure (CRF), including patients on dialysis and patients not on dialysis, and for the treatment of anemia in patients with nonmyeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy.Important Product Safety InformationAranesp® is contraindicated in patien...

Orasi Medical

Orasi Medical develops products to measure the effect of neurological treatments and track the progression of neurological disorders. Pharmaceutical companies use Orasi Index(TM), the company's flagship product, to reduce costs and improve clinical development of neurological treatments. Orasi's high-resolution measurement of brain function provides a robust, non-invasive and reproducible measure ...

APO-T B.V. and LinXis B.V.

APO-T is a biopharmaceutical company focused on the development and commercialization of proprietary biotherapeutics for oncology. APO-T has developed fully-human antibodies and antibody fragments that target any tumor cell that expresses a MAGE-A peptide in the context of MHC-1. Many different kinds of tumors expose this MAGE-MHC-1 peptide complex. They a...

Probably Relevant

Numab

Founded in 2011, Numab discovers and develops innovative antibody-based therapeutics. Applying proprietary rabbit-based antibody discovery and engineering technology, Numab generates highly potent and stable antibody Fv fragments, which serve as building blocks to create mono- or bi-specific antibody fragment-based therapeutics with tailored pharmacokineti...

Tosk Inc.

Tosk was founded in 1998 to discover new drugs for genetic diseases and cancer. The original technology, in part licensed from Stanford University,StealthGene and Targeted Gene Delivery technologies. In the process, Tosk discovered and perfected the Optimizing Marketed Drugs side-effect-reducing drugs.Tosk's current drug discovery and development efforts focus on applying the OMD approach to disco...

HealthSparq

HealthSparq is creating a revolution in helping people make smarter, more educated choices about their health care. By enabling people to see the total costs of care (pre- and post-procedure included), comparison shop for procedures and providers and learn about alternative care options, HealthSparq is helping people navigate the health care system and sho...

Happy Hour Effect

Happy Hour Effect LLC

Mpex Pharmaceuticals, Inc.

Mpex Pharmaceuticals is a clinical stage biopharmaceutical company whose mission is to develop important new therapies to combat the growing issue of antibiotic resistance. The company's internal development pipeline focuses on combining proprietary formulations, PK/PD strategies and novel potentiating agents with proven antibiotics to overcome or directly inhibit the molecular mechanisms in bacte...

NovaDel Pharma Inc.

NovaDel Pharma Inc. is a specialty pharmaceutical company developing oral spray formulations for a broad range of marketed drugs. The Company’s proprietary technology offers, in comparison to conventional oral dosage forms, the potential for faster absorption of drugs into the bloodstream leading to quicker onset of therapeutic effects and possibly re...

Debiopharm Group

Debio 025 is an oligopeptide that has some chemical features in common with cyclosporine A, but is devoid of its immunosuppressive pharmacological effects. It has a very potent inhibitory effect on HCV replication both in vitro and in vivo. Debio 025 has excellent antiviral activity against a broad range of genotypes (1, 2, 3 and 4); a high barrier to the development of resistance; and the pos...

Genaissance Pharmaceuticals Incorporated

Genaissance is a leader in establishing the new field of personalized medicine through the application of population genomics and informatics. From the discovery of proprietary "genomic bar codes" that are predictive of which patients will respond or develop a side effect to a particular medication, the company is working to improve the development, marketing and prescribing of drugs. Genaissance ...

NephRx Corporation

NephRx Corporation is a biotechnology company dedicated to the discovery and development of therapeutic products for the treatment of acute kidney failure and other renal disorders and diseases of the gastrointestinal tract, including mucositis, Crohn's disease and ulcerative colitis. Lead product NX001 is a kidney growth factor peptide for acute renal failure that is currently in preclinical dev...

CorMedix Inc.

CorMedix Inc. is a pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of cardiac and renal dysfunction, also known as cardiorenal disease. CorMedix’s goal is to treat kidney disease by reducing the commonly associated cardiovascular and metabolic complications, in effect, tr...

GelTex Incorporated

We are dedicated to having a positive effect on the lives of people living with illness and disease. We have demonstrated this by bringing important new therapies from discovery to market. GelTex’s first product, Renagel® brand sevelamer hydrochloride, was granted marketing approval by the U.S. Food and Drug Administration (FDA) in October 1998 for the reduction of serum phosphorus in hemodialy...

MeiraGTx

MeiraGTx is committed to the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. The company is developing potential treatments for ocular diseases, including rare inherited blindness and age-related macular degeneration (AMD). MeiraGTx is also developing potential treatments for xerostomi...

Protalex, Inc.

Protalex, Inc. is a clinical stage biopharmaceutical company that is developing a class of biopharmaceutical drugs for treating autoimmune and inflammatory diseases, including but not limited to, rheumatoid arthritis. Protalex’s lead product PRTX-100, which is formulated with a highly-purified form of staphylococcal protein A, has completed a Phase 1b...

MeiraGTx Limited

MeiraGTx is committed to the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. The company is developing potential treatments for ocular diseases, including rare inherited blindness and age-related macular degeneration (AMD). MeiraGTx is also developing potential treatments for xerostomi...

The Patients Association

The Patients Association is a registered charity, staffed by paid and unpaid staff. The Patients Association offers patients an opportunity to share their experiences of health services. The Patients Association uses the knowledge it gains from patients to work with the NHS and other healthcare providers to improve services. The Patients Association works with a range of organisations providing he...


More From BioPortfolio on "Comparison of the Effect Between Levofloxacin and Moxifloxacin Among MDR-TB Patients"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks